OncoZenge AB stock analysis
Want to see SE:ONCOZ full AI Analyst Report?
OncoZenge AB (ONCOZ) Stock Price & Analysis
ONCOZ Stock Chart & Stats
- Day’s Range
- SEK 3.08 - SEK 3.38
- 52-Week Range
- SEK 2.81 - SEK 8.58
- Previous Close
- SEK 3.30
- Volume
- N/A
- Average Volume (3M)
- 69.36K
- Market Cap
- SEK 91.08M
- Enterprise Value
- SEK 108.32M
- Total Cash (Recent Filing)
- SEK 749.00K
- Total Debt (Recent Filing)
- SEK 7.50M
- Price to Earnings (P/E)
- ―
- Beta
- 1.45
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Revenue growth indicates improving commercialization traction and broader adoption of the company’s offerings. Although the base remains small, continued expansion could strengthen operating leverage and provide a larger platform for funding development and commercialization over the next several quarters.
Positive Gross Profit
Positive gross profit shows that sales are generating economic contribution before operating costs, providing an important foundation for future scale. If revenue continues rising, this gross-profit base could help absorb fixed development and commercial expenses over time.
Specialized Oncology Product Focus
A focused oncology supportive-care strategy gives the company a clearly defined therapeutic purpose and product direction. Concentration on severe cancer-treatment pain may support specialized expertise, targeted commercialization, and durable positioning within this specific care need.
Bears Say
Persistent Net Losses
The scale of ongoing net losses relative to revenue shows that the current business is not yet economically self-sustaining. Persistent losses can delay profitability, constrain reinvestment, and require continued financing while the company develops and commercializes its products.
Heavy Cash Burn
Substantial operating and free-cash-flow deficits indicate that the company continues consuming cash to fund its operations and development activity. Continued burn at this revenue scale increases dependence on external capital and may restrict flexibility in executing its growth plans.
Negative Equity And Elevated Leverage
Negative equity is a material solvency warning because liabilities exceed recorded assets, leaving limited balance-sheet flexibility. With debt outstanding and leverage elevated against negative equity, the company may face greater pressure when funding operations or absorbing further losses.
OncoZenge AB News
ONCOZ FAQ
What was OncoZenge AB’s price range in the past 12 months?
What is OncoZenge AB’s market cap?
When is OncoZenge AB’s upcoming earnings report date?
How were OncoZenge AB’s earnings last quarter?
Is OncoZenge AB overvalued?
Does OncoZenge AB pay dividends?
What is OncoZenge AB’s EPS estimate?
How many shares outstanding does OncoZenge AB have?
What happened to OncoZenge AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of OncoZenge AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
OncoZenge AB
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stian Kildal
- Employees
- 1
- Website
- www.oncozenge.se
- Address
- Gustavslundsvagen 34, Bromma, AB, 167 51, SE
OncoZenge AB (ONCOZ) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 5 | 11 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 4 | 0 | 8 |
